Spruce Biosciences Q3 Net Loss Widens on Higher R&D Costs
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…
Story updates
01:13:29 PM UTC
SquawkNews
Spruce Biosciences reported a third-quarter 2026 net loss of $24.0 million, compared with $8.2 million a year earlier, and ended September with $87.7 million in cash and cash equivalents. The company said its planned December 2026 BLA submission for TA-ERT remains on track. It also announced an ame…
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…